NMDAR-independent, cAMP-dependent antidepressant actions of ketamine

Mol Psychiatry. 2019 Dec;24(12):1833-1843. doi: 10.1038/s41380-018-0083-8. Epub 2018 Jun 12.

Abstract

Ketamine produces rapid and robust antidepressant effects in depressed patients within hours of administration, often when traditional antidepressant compounds have failed to alleviate symptoms. We hypothesized that ketamine would translocate Gαs from lipid rafts to non-raft microdomains, similarly to other antidepressants but with a distinct, abbreviated treatment duration. C6 glioma cells were treated with 10 µM ketamine for 15 min, which translocated Gαs from lipid raft domains to non-raft domains. Other NMDA antagonist did not translocate Gαs from lipid raft to non-raft domains. The ketamine-induced Gαs plasma membrane redistribution allows increased functional coupling of Gαs and adenylyl cyclase to increase intracellular cyclic adenosine monophosphate (cAMP). Moreover, increased intracellular cAMP increased phosphorylation of cAMP response element-binding protein (CREB), which, in turn, increased BDNF expression. The ketamine-induced increase in intracellular cAMP persisted after knocking out the NMDA receptor indicating an NMDA receptor-independent effect. Furthermore, 10 µM of the ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) also induced Gαs redistribution and increased cAMP. These results reveal a novel antidepressant mechanism mediated by acute ketamine treatment that may contribute to ketamine's powerful antidepressant effect. They also suggest that the translocation of Gαs from lipid rafts is a reliable hallmark of antidepressant action that might be exploited for diagnosis or drug development.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antidepressive Agents / pharmacology
  • Brain-Derived Neurotrophic Factor / metabolism
  • Cell Line
  • Cyclic AMP / metabolism
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Depression / drug therapy
  • Glioma / metabolism
  • Humans
  • Ketamine / pharmacology*
  • Membrane Microdomains / drug effects
  • Receptors, N-Methyl-D-Aspartate / metabolism*

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • CREB1 protein, human
  • Cyclic AMP Response Element-Binding Protein
  • Receptors, N-Methyl-D-Aspartate
  • Ketamine
  • BDNF protein, human
  • Cyclic AMP